Why Choosing A Client-Centric CTDMO Is Critical When Outsourcing Biomanufacturing Projects

Biologic drug development, encompassing monoclonal antibodies and other large molecules produced in mammalian cells, is experiencing significant growth. While certain biologic drugs have established manufacturing processes, biomanufacturers still face a number of challenges and bottlenecks with bioprocess optimization, capacity limitations, supply chain hurdles, and regulatory requirements.

A promising solution for companies that lack the technical expertise and comprehensive in-house capacity to address these issues is outsourcing various drug development phases to an end-to-end specialized Contract Testing, Development, and Manufacturing Organization (CTDMO). A CTDMO can serve as either a service provider or a collaborative partner in strategic thinking. Thus, selecting the right CTDMO partner is crucial for the success of the biomanufacturing project.